Evidence map›Paper›PMID 28701420›Full record

ArticleJournal of clinical microbiology2017

Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains.

Lavinia Fabeni, Giulia Berno, Joseph Fokam, Ada Bertoli, Claudia Alteri, Caterina Gori, Federica Forbici, Desiré Takou, Alessandra Vergori, Mauro Zaccarelli and 12 more

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Lavinia FabeniNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy lavinia.fabeni@gmail.com.
Giulia BernoNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
Joseph FokamChantal Biya International Reference for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
Ada BertoliUniversity of Rome Tor Vergata, Rome, Italy.
Claudia AlteriUniversity of Rome Tor Vergata, Rome, Italy.
Caterina GoriNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
Federica ForbiciNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
Desiré TakouChantal Biya International Reference for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
Alessandra VergoriNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
Mauro ZaccarelliNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
Gaetano MaffongelliUniversity Hospital Tor Vergata, Rome, Italy.
Vanni BorghiModena University Hospital, Modena, Italy.
Alessandra LatiniSan Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Alfredo PennicaS. Andrea Hospital, Rome, Italy.
Claudio Maria MastroianniPolo Pontino-Sapienza University, Latina, Italy.
Francesco MontellaS. Giovanni Addolorata Hospital, Rome, Italy.
Cristina MussiniModena University Hospital, Modena, Italy.
Massimo AndreoniUniversity Hospital Tor Vergata, Rome, Italy.
Andrea AntinoriNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
Carlo Federico PernoNational Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
Maria Mercedes SantoroUniversity of Rome Tor Vergata, Rome, Italy.
Resistance Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV-1 non-B subtypes/circulating recombinant forms (CRFs) are increasing worldwide. Since subtype identification can be clinically relevant, we assessed the added value in HIV-1 subtyping using updated molecular phylogeny (Mphy) and the performance of routinely used automated tools. Updated Mphy (2015 updated reference sequences), used as a gold standard, was performed to subtype 13,116 HIV-1 protease/reverse transcriptase sequences and then compared with previous Mphy (reference sequences until 2014) and with COMET, REGA, SCUEAL, and Stanford subtyping tools. Updated Mphy classified subtype B as the most prevalent (73.4%), followed by CRF02_AG (7.9%), C (4.6%), F1 (3.4%), A1 (2.2%), G (1.6%), CRF12_BF (1.2%), and other subtypes (5.7%). A 2.3% proportion of sequences were reassigned as different subtypes or CRFs because of misclassification by previous Mphy. Overall, the tool most concordant with updated Mphy was Stanford-v8.1 (95.4%), followed by COMET (93.8%), REGA-v3 (92.5%), Stanford-old (91.1%), and SCUEAL (85.9%). All the tools had a high sensitivity (≥98.0%) and specificity (≥95.7%) for subtype B. Regarding non-B subtypes, Stanford-v8.1 was the best tool for C, D, and F subtypes and for CRFs 01, 02, 06, 11, and 36 (sensitivity, ≥92.6%; specificity, ≥99.1%). A1 and G subtypes were better classified by COMET (92.3%) and REGA-v3 (98.6%), respectively. Our findings confirm Mphy as the gold standard for accurate HIV-1 subtyping, although Stanford-v8.1, occasionally combined with COMET or REGA-v3, represents an effective subtyping approach in clinical settings. Periodic updating of HIV-1 reference sequences is fundamental to improving subtype characterization in the context of an effective epidemiological surveillance of non-B strains.

Indexed as

Automation, LaboratoryBase SequenceDatabases, GeneticHIV-1HIV InfectionsHIV ProteaseHIV Reverse TranscriptaseHumansMolecular TypingPhylogenySensitivity and SpecificitySequence Analysis, RNAHIV ProteaseHIV Reverse Transcriptasep16 protease, Human immunodeficiency virus 1reverse transcriptase, Human immunodeficiency virus 1circulating recombinant formsgenetic diversityHIV-1phylogenysubtypessubtyping automated tools

Identifiers

PMID28701420
PMCPMC5648718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.